Current antiviral therapies for chronic hepatitis B

Hepatology Research

Volumn 38, Issue 6, 2008, Pages 535-542

  Inada, Mari ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Adefovir; Clevudine; Entecavir; Lamivudine; Telvibudine; Tenefovir

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; CLEVUDINE; ENTECAVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIVIRAL RESISTANCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROSS RESISTANCE; DRUG CHOICE; DRUG EFFICACY; DRUG TOLERABILITY; ERADICATION THERAPY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MEDICAL DECISION MAKING; MONOTHERAPY; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 43049145846     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00323.x     Document Type: Review

References (97)

1. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995; 13(Suppl. 1): S47-9.
2. Lok AS. Chronic hepatitis B. N Engl J Med 2002; 346: 1682-3.
3. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
4. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
5. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60.
6. Bertoletti A, Gehring A. Immune response and tolerance during chronic hepatitis B virus infection. Hepatol Res 2007; 37(Suppl 3): S331-8.
7. Ayada M, Ishikawa T, Okumura A et al. Alteration of serum cytokine balances among different phases of chronic hepatitis B virus infection. Hepatol Res 2006; 34(4): 214-21.
8. Guo H, Jiang D, Zhou T, Cuconati A, Block TM, Guo JT. Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: An intermediate of covalently closed circular DNA formation. J Virol 2007; 81(22): 12472-84.
9. Yokosuka O, Omata M, Imazeki F, Okuda K. Active and inactive replication of hepatitis B virus deoxyribonucleic acid in chronic liver disease. Gastroenterology 1985; 89(3): 610-6.
10. Yokosuka O, Omata M, Imazeki F, Ito Y, Okuda K. Hepatitis B virus RNA transcripts and DNA in chronic liver disease. N Engl J Med 1986; 315(19): 1187-92.
11. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 29(2): 403-15.
12. Wright TL. Antiviral therapy and primary and secondary prevention of hepatocellular carcinoma. Hepatol Res 2007; 37(Suppl 2): S294-8.
13. Gish RG. Improving outcomes for patients with chronic hepatitis B. Hepatol Res 2007; 37(s1): S67-78.
14. Koga H, Ide T, Oho K et al. Lamivudine treatment-related morphological changes of esophageal varices in patients with liver cirrhosis. Hepatol Res 2007; 37(7): 503-9.
15. Kubo S, Tanaka H, Takemura S et al. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res 2007; 37(2): 94-100.
16. Akbar F, Yoshida O, Abe M, Hiasa Y, Onji M. Engineering immune therapy against hepatitis B virus. Hepatol Res 2007; 37(Suppl 3): S351-6.
17. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B. N Engle J Med 1996; 334: 1422-7.
18. Kao JH. Appropriate use of interferon for treatment of chronic hepatitis B. Hepatol Res 2007; 37(s1): S47-54.
19. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998-1002.
20. Wai CT, Chu CJ, Hussain M, Lok AS et al. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36: 1425-30.
21. Erhardt A, Reineke U, Blondin D et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31: 716-25.
22. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101: 297-303.
23. Orito E, Mizokami M. Differences of HBV genotypes and hepatocellular carcinoma in Asian countries. Hepatol Res 2007; 37(s1): S33-5.
24. Shin-I T, Tanaka Y, Tateno Y, Mizokami M. Development and public release of a comprehensive hepatitis virus database. Hepatol Res 2008; 38: 234-43.
25. Orito E, Mizokami M, Sakugawa H et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001; 33: 218-33.
26. Sumi H, Yokosuka O, Seki N et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003; 37: 19-26.
27. Orito E, Sugauchi F, Tanaka Y et al. Differences of hepatocellular carcinoma patients with hepatitis B virus genotypes of Ba, Bj or C in Japan. Intervirology 2005; 4: 239-45.
28. Matsuura K, Michitaka K, Yamauchi K et al. Characteristics of geographic distributions and route of infection for hepatitis B virus genotype D in Ehime area in western Japan. Hepatol Res 2007; 37(4): 255-62.
29. Sugauchi F, Orito E, Ohno T et al. Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. Hepatol Res 2006; 36(2): 107-14.
30. Yokosuka O, Omata M, Imazeki F, Okuda K, Summers J. Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: Analysis of intrahepatic replicative hepatitis B virus DNA. Hepatology 1985; 5(5): 728-34.
31. Hatakeyama T, Noguchi C, Hiraga N et al. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. Hepatology 2007; 45(5): 1179-86.
32. Orito E, Fujiwara K, Tanaka Y et al. A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Hepatol Res 2006; 35: 127-34.
33. Enomoto M, Tamori A, Nishiguchi S. Hepatitis B virus genotypes and response to antiviral therapy. Clin Lab 2006; 52(1-2): 43-7.
34. Lok AS, McMahon BJ. Chronic hepatitis B: Update of recommendations. Hepatology 2004; 39: 857-61.
35. Minami M, Okanoue T. Management of HBV infection in Japan. Hepatol Res 2007; 37(s1): S79-82.
36. Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889-96.
37. Chen CH, Lee CM, Lu SN et al. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. J Hepatol 2004; 41: 454-61.
38. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen - negative chronic hepatitis B. Hepatology 2000; 32: 847-51.
39. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 219-26.
40. Di Marco V, Marzano A, Lampertico P et al. Clinical outcome of HBeAg negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883-91.
41. Orito E, Fujiwara K, Tanaka Y et al. A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Hepatol Res 2006; 35: 127-34.
42. Kobayashi M, Suzuki F, Akuta N. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C. J Med Virol 2006; 78: 1276-83.
43. Marcellin P, Lada O, Asselah T. Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine. Hepatol Res 2007; 37(s1): S55-61.
44. Ishikawa T, Kakumu S. Combination therapy with lamivudine and HB vaccine on chronic hepatitis B. Hepatol Res 2007; 37(s1): S62-6.
45. Matsumoto A, Tanaka E, Minami M et al. Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. Hepatol Res 2007; 37(8): 661-6.
46. Shinkai N, Tanaka Y, Orito E et al. Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. Hepatol Res 2006 Dec; 36(4): 272-6. Sep 12 [Epub 2006].
47. Kramata P, Votruba I, Otova B, Holy A. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon. Mol Pharmacol 1996; 46: 1005-11.
48. Heijtink RA, De Wilde GA, Kruining J et al. Inhibitory effect of 9-(2-phosphonylmethoxyethyl) - adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res 1993; 21: 141-53.
49. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
50. Bzowej N, Chan H, Lai CL et al. A randomized trial of telbivudine vs. adefovir for HBeAg-positive chronic hepatitis B: Week 52 results. Hepatology 2006; 44: 563A.
51. Lee YS, Suh DJ, Lim YS et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 1385-91.
52. Zeng M, Mao Y, Yao G et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006; 44: 108-16.
53. Westland C, Delaney W, Yang H et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 2002; 125: 107-16.
54. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
55. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673-81.
56. Macellin P, Chang TT, Lim S et al. Long term efficacy and safety of adefovir dipivoxil 10 mg in HBeAg + chronic hepatitis B patients: increasing serologic, virologic and biochemical response over time. J Hepatol 2004; 40(Suppl. 4): 655A.
57. Takamura M, Ichida T, Ohkoshi S et al. Decompensated lamivudine-resistant hepatitis B virus-related cirrhosis treated successfully with adefovir dipivoxil allowing surgery for hepatocellular carcinoma. Intern Med 2007; 46(7): 367-71.
58. Suzuki F, Kumada H, Nakamura H. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy. J Med Virol 2006; 78(8): 1025-34.
59. Perrillo R, Schiff E, Yoshida E et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-34.
60. Walsh KM, Woodall T, Lamy P, Wight DG, Bloor S, Alexander GJ. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001; 49: 436-40.
61. Peters MG, Hann Hw H, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101.
62. Marzano A, Gaia S, Barbon V et al. Therapy with adefovir alone or combined with lamivudine in patients with lamivudine-resistant chronic hepatitis B: Clinical and virological aspects. Hepatology 2006; 44: 231A. (Abstract 113).
63. Lee YS, Chung Y, Ryu S et al. Hepatitis B virus with rtL80V/I mutation associates with poor response to adefovir dipivoxil therapy. Hepatology 2005; 42(Suppl. 1): 575A.
64. Lada O, Benhamou Y, Cahour A et al. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004; 9: 353-63.
65. Ono SK, Kato N, Shiratori Y et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 102: 449-55.
66. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE 4th. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10: 625-33.
67. Fung SK, Chae HB, Fontana RJ et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283-90.
68. Colonno RJ, Genovesi EV, Medina I et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001; 184: 1236-45.
69. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
70. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. New Engl J Med 2006; 354: 1011-20.
71. Colonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44: 1656-65.
72. Tenney DJ, Rose RE, Baldick CJ. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 902-11.
73. Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48: 3498-507.
74. Nagasaki F, Niitsuma H, Ueno Y, Inoue J, Kogure T, Fukushima K, Shimosegawa T. The high incidence of the emergence of entecavir-resistant mutants among patients infected with lamivudine-resistant hepatitis B virus. Tohoku J Exp Med 2007; 213(2): 181-6.
75. Yatsuji H, Hiraga N, Mori N et al. Successful treatment of an entecavir-resistant hepatitis B virus variant. J Med Virol 2007; 79(12): 1811-7.
76. Lai CL, Lim SG, Brown NA et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004; 40(3): 719-26.
77. Lai CL, Leung N, Teo EK et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129(2): 528-36.
78. Chan HL, Heathcote EJ, Marcellin P et al. and the 018 Study Group*. Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis with Telbivudine or Adefovir: A Randomized Trial. Ann Intern Med 2007; 147: 745-54.
79. Lai CL, Leung NW, Teo EK et al. Phase Iib extended-treatment trial of telbivudine (LdT) vs lamivudine vs. combination treatment in hepatitis B patients: Two year results. Gastroenterology 2005; 128: A692 (Abstract).
80. Colonno RJ, Rose FE, Baldick CJ et al. High barrier to resistance results in no emergence of entecavir resistance in nucleoside-naïve subjects during the first two years of therapy. J Hepatol 2006; 44(Suppl. 2): S182.
81. Song BC, Suh DJ, Lee HC et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 30: 803-6.
82. Ryu SH, Chung YH, Choi MH et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: A prospective study. J Hepatol 2003; 39: 614-19.
83. Chang TT, Schiffman ML, Tong M et al. Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B. J Hepatol 2006; 44(Suppl. 2): S187.
84. Fung SK, Wong F, Hussain M, Lok AS et al. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004; 11: 432-8.
85. Yoo BC, Kim JH, Chung YH et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007; 45: 1172-8.
86. Lee HS, Chung YH, Lee K et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2006; 43(5): 982-8.
87. Yoo BC, Kim JH, Kim TH et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007; 46(4): 1041-8.
88. Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomized trial. Lancet 2005; 365: 123-9.
89. Lau GK, Piratvisuth T, Luo KX et al. Peg interferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
90. Marcellin P, Lau GK, Bonino F et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
91. Bortolotti F, Jara P, Barbera C et al. Long term effect of alpha interferon in children with chronic hepatitis B. Gut 2000; 46: 715-18.
92. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 306-13.
93. Brunetto MR, Oliveri F, Coco B et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long-term cohort study. J Hepatol 2002; 36: 263-70.
94. van Bommel F, Wunsche T, Mauss S et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 1421-5.
95. van Bömmel F, Zöllner B, Sarrazin C et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV-DNA level during adefovir therapy. Hepatology 2006; 44(2): 318-25.
96. Peters MG, Andersen J, Lynch P et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127 Hepatology 2006; 44(5): 1110-6.
97. Benhamou Y, Fleury H, Trimoulet P et al. TECOVIR Study Group. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006; 43(3): 548-55.